Literature DB >> 17947312

Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load.

Austen J Milnerwood1, Lynn A Raymond.   

Abstract

Huntington's disease (HD) is an autosomal dominant, late onset, neurodegenerative disease characterized by motor deficits and dementia that is caused by expansion of a CAG repeat in the HD gene. Clinical manifestations result from selective neuronal degeneration of predominantly GABAergic striatal medium-sized spiny neurons (MSNs). A growing number of studies demonstrate that personality, mood and cognitive disturbances are some of the earliest signs of HD and may reflect synaptic dysfunction prior to neuronal loss. Previous studies in striatal MSNs demonstrated early alterations in NMDA-type glutamate receptor currents in several HD mouse models, as well as evidence for presynaptic dysfunction prior to disease manifestations in the R6/2 HD fragment mouse model. We have compared corticostriatal synaptic function in full-length, human HD gene-carrying YAC transgenic mice expressing a non-pathogenic CAG repeat (YAC18; control) with three increasingly severe variants of pathogenic HD gene-expressing mice (YAC72 and two different lines of YAC128), at ages that precede any detectable disease phenotype. We report presynaptic dysfunction and a propensity towards synaptic depression in YAC72 and YAC128 compared to YAC18 mice, and, in the most severe model, we also observed altered AMPA receptor function. When normalized to evoked AMPAR currents, postsynaptic NMDAR currents are augmented in all three pathogenic HD YAC variants. These findings demonstrate multiple perturbations to corticostriatal synaptic function in HD mice, furthering our understanding of the early effects of the HD mutation that may contribute to cognitive dysfunction, mood disorders and later development of more serious dysfunction. Furthermore, this study provides a set of neurophysiological sequelae against which to test and compare other mouse models and potential therapies in HD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17947312      PMCID: PMC2375504          DOI: 10.1113/jphysiol.2007.142448

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  100 in total

1.  Impaired synaptic plasticity in mice carrying the Huntington's disease mutation.

Authors:  M T Usdin; P F Shelbourne; R M Myers; D V Madison
Journal:  Hum Mol Genet       Date:  1999-05       Impact factor: 6.150

Review 2.  The glutamate receptor ion channels.

Authors:  R Dingledine; K Borges; D Bowie; S F Traynelis
Journal:  Pharmacol Rev       Date:  1999-03       Impact factor: 25.468

3.  Synaptic vesicles recycling spontaneously and during activity belong to the same vesicle pool.

Authors:  Teja W Groemer; Jurgen Klingauf
Journal:  Nat Neurosci       Date:  2007-01-14       Impact factor: 24.884

4.  Functional and pharmacological differences between recombinant N-methyl-D-aspartate receptors.

Authors:  S Vicini; J F Wang; J H Li; W J Zhu; Y H Wang; J H Luo; B B Wolfe; D R Grayson
Journal:  J Neurophysiol       Date:  1998-02       Impact factor: 2.714

5.  A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration.

Authors:  J G Hodgson; N Agopyan; C A Gutekunst; B R Leavitt; F LePiane; R Singaraja; D J Smith; N Bissada; K McCutcheon; J Nasir; L Jamot; X J Li; M E Stevens; E Rosemond; J C Roder; A G Phillips; E M Rubin; S M Hersch; M R Hayden
Journal:  Neuron       Date:  1999-05       Impact factor: 17.173

6.  Increased contribution of NR2A subunit to synaptic NMDA receptors in developing rat cortical neurons.

Authors:  G Stocca; S Vicini
Journal:  J Physiol       Date:  1998-02-15       Impact factor: 5.182

7.  Huntingtin-interacting protein HIP14 is a palmitoyl transferase involved in palmitoylation and trafficking of multiple neuronal proteins.

Authors:  Kun Huang; Anat Yanai; Rujun Kang; Pamela Arstikaitis; Roshni R Singaraja; Martina Metzler; Asher Mullard; Brendan Haigh; Catherine Gauthier-Campbell; Claire-Anne Gutekunst; Michael R Hayden; Alaa El-Husseini
Journal:  Neuron       Date:  2004-12-16       Impact factor: 17.173

8.  Abnormal cortical synaptic plasticity in a mouse model of Huntington's disease.

Authors:  Damian M Cummings; Austen J Milnerwood; Glenn M Dallérac; Sarat C Vatsavayai; Mark C Hirst; Kerry P S J Murphy
Journal:  Brain Res Bull       Date:  2006-11-16       Impact factor: 4.077

9.  Huntingtin interacting protein 14 is an oncogenic human protein: palmitoyl acyltransferase.

Authors:  Charles E Ducker; Erin M Stettler; Kevin J French; John J Upson; Charles D Smith
Journal:  Oncogene       Date:  2004-12-09       Impact factor: 9.867

10.  Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models.

Authors:  Anatol C Kreitzer; Robert C Malenka
Journal:  Nature       Date:  2007-02-08       Impact factor: 49.962

View more
  58 in total

1.  A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.

Authors:  Damian M Cummings; Yasaman Alaghband; Miriam A Hickey; Prasad R Joshi; S Candice Hong; Chunni Zhu; Timothy K Ando; Véronique M André; Carlos Cepeda; Joseph B Watson; Michael S Levine
Journal:  J Neurophysiol       Date:  2011-11-09       Impact factor: 2.714

2.  Differential electrophysiological changes in striatal output neurons in Huntington's disease.

Authors:  Véronique M André; Carlos Cepeda; Yvette E Fisher; My Huynh; Nora Bardakjian; Sumedha Singh; X William Yang; Michael S Levine
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

Review 3.  Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease?

Authors:  H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Nathanael Hevelone; Steven M Hersch
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

4.  Hyperactivity and cortical disinhibition in mice with restricted expression of mutant huntingtin to parvalbumin-positive cells.

Authors:  S E Dougherty; J J Hollimon; L J McMeekin; A S Bohannon; A B West; M Lesort; J J Hablitz; R M Cowell
Journal:  Neurobiol Dis       Date:  2013-10-11       Impact factor: 5.996

Review 5.  Hyperkinetic disorders and loss of synaptic downscaling.

Authors:  Paolo Calabresi; Antonio Pisani; John Rothwell; Veronica Ghiglieri; Josè A Obeso; Barbara Picconi
Journal:  Nat Neurosci       Date:  2016-06-28       Impact factor: 24.884

6.  The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.

Authors:  Daniel Ryskamp; Jun Wu; Michal Geva; Rebecca Kusko; Iris Grossman; Michael Hayden; Ilya Bezprozvanny
Journal:  Neurobiol Dis       Date:  2016-11-03       Impact factor: 5.996

7.  The mGluR5 positive allosteric modulator VU0409551 improves synaptic plasticity and memory of a mouse model of Huntington's disease.

Authors:  Juliana G Doria; Jessica M de Souza; Flavia R Silva; Isabella G Olmo; Toniana G Carvalho; Juliana Alves-Silva; Talita H Ferreira-Vieira; Jessica T Santos; Claudymara Q S Xavier; Nathalia C Silva; Esther M A Maciel; Peter Jeffrey Conn; Fabiola M Ribeiro
Journal:  J Neurochem       Date:  2018-09-11       Impact factor: 5.372

8.  Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease.

Authors:  J Spampanato; X Gu; X W Yang; I Mody
Journal:  Neuroscience       Date:  2008-09-18       Impact factor: 3.590

9.  Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease.

Authors:  Damian M Cummings; Carlos Cepeda; Michael S Levine
Journal:  ASN Neuro       Date:  2010-06-18       Impact factor: 4.146

Review 10.  Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms.

Authors:  Carlos Cepeda; Damian M Cummings; Véronique M André; Sandra M Holley; Michael S Levine
Journal:  ASN Neuro       Date:  2010-04-07       Impact factor: 4.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.